当前位置:
X-MOL 学术
›
J. Med. Chem.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2019-08-05 00:00:00 , DOI: 10.1021/acs.jmedchem.9b00687 Yunhang Guo , Ye Liu , Nan Hu , Desheng Yu , Changyou Zhou , Gongyin Shi , Bo Zhang , Min Wei , Junhua Liu , Lusong Luo , Zhiyu Tang , Huipeng Song , Yin Guo , Xuesong Liu , Dan Su , Shuo Zhang , Xiaomin Song , Xing Zhou , Yuan Hong , Shuaishuai Chen , Zhenzhen Cheng , Steve Young , Qiang Wei , Haisheng Wang , Qiuwen Wang , Lei Lv , Fan Wang , Haipeng Xu , Hanzi Sun , Haimei Xing , Na Li , Wei Zhang , Zhongbo Wang , Guodong Liu , Zhijian Sun , Dongping Zhou , Wei Li , Libin Liu , Lai Wang , Zhiwei Wang
Journal of Medicinal Chemistry ( IF 6.8 ) Pub Date : 2019-08-05 00:00:00 , DOI: 10.1021/acs.jmedchem.9b00687 Yunhang Guo , Ye Liu , Nan Hu , Desheng Yu , Changyou Zhou , Gongyin Shi , Bo Zhang , Min Wei , Junhua Liu , Lusong Luo , Zhiyu Tang , Huipeng Song , Yin Guo , Xuesong Liu , Dan Su , Shuo Zhang , Xiaomin Song , Xing Zhou , Yuan Hong , Shuaishuai Chen , Zhenzhen Cheng , Steve Young , Qiang Wei , Haisheng Wang , Qiuwen Wang , Lei Lv , Fan Wang , Haipeng Xu , Hanzi Sun , Haimei Xing , Na Li , Wei Zhang , Zhongbo Wang , Guodong Liu , Zhijian Sun , Dongping Zhou , Wei Li , Libin Liu , Lai Wang , Zhiwei Wang
![]() |
Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematological malignancies. The discovery of a more selective on-target covalent BTK inhibitor is of high value. Herein, we disclose the discovery and preclinical characterization of a potent, selective, and irreversible BTK inhibitor as our clinical candidate by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compounds. Compound BGB-3111 (31a, Zanubrutinib) demonstrates (i) potent activity against BTK and excellent selectivity over other TEC, EGFR and Src family kinases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenograft models.
中文翻译:
Zanubrutinib(BGB-3111)是Bruton酪氨酸激酶的新型,有效和选择性共价抑制剂的发现。
布鲁顿酪氨酸激酶(BTK)的异常激活在B细胞淋巴瘤的发病机理中起重要作用,这表明抑制BTK可用于治疗血液系统恶性肿瘤。发现更具选择性的靶标共价BTK抑制剂具有很高的价值。本文中,我们通过使用体外效价,选择性,药代动力学(PK)和体内药效学来确定化合物的优先级,公开了一种有效,选择性和不可逆的BTK抑制剂作为我们的临床候选药物的发现和临床前表征。化合物BGB-3111(31a,Zanubrutinib)表现出(i)对BTK的有效活性以及对其他TEC,EGFR和Src家族激酶的出色选择性,(ii)理想的ADME,在小鼠中具有出色的体内药效学和在OCI-LY10异种移植模型中的功效。
更新日期:2019-08-05
中文翻译:

Zanubrutinib(BGB-3111)是Bruton酪氨酸激酶的新型,有效和选择性共价抑制剂的发现。
布鲁顿酪氨酸激酶(BTK)的异常激活在B细胞淋巴瘤的发病机理中起重要作用,这表明抑制BTK可用于治疗血液系统恶性肿瘤。发现更具选择性的靶标共价BTK抑制剂具有很高的价值。本文中,我们通过使用体外效价,选择性,药代动力学(PK)和体内药效学来确定化合物的优先级,公开了一种有效,选择性和不可逆的BTK抑制剂作为我们的临床候选药物的发现和临床前表征。化合物BGB-3111(31a,Zanubrutinib)表现出(i)对BTK的有效活性以及对其他TEC,EGFR和Src家族激酶的出色选择性,(ii)理想的ADME,在小鼠中具有出色的体内药效学和在OCI-LY10异种移植模型中的功效。